COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE

Author(s)

Sánchez-Pedraza V¹, Hansen BB², Gundgaard J², García Uranga Romano J³, Evans M⁴
¹Hospital General de México, México City, Mexico, ²Novo Nordisk A/S, Søborg, Denmark, ³Novo Nordisk México, Mexico City, Mexico, ⁴University Hospital Llandough, Cardiff, UK

Presentation Documents

PDB43-sanchez-pedraza-v-sup-1-sup-strong-u-hansen-bb-u-sup-2-sup-strong-gundgaard-j-sup-2-sup-garcia-uranga-romano-j-sup-3-sup-evans-m-sup-4-sup-br-sup-1-sup-hospital-general-de-mexico-mexico-city-mexico-sup-2-sup-novo-nordisk-a-s-soborg-de ...

OBJECTIVES:

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PDB43

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation